Trial Profile

A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IVX 037 (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors ImmVirX

Most Recent Events

25 Mar 2026 Planned End Date changed from 30 Nov 2026 to 30 Nov 2028.
25 Mar 2026 Planned primary completion date changed from 30 Sep 2026 to 30 Jun 2028.
30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com